Hemispherx Biopharma to Present At Fall 2006 Micro Cap Conference.

PHILADELPHIA -- Hemispherx Biopharma, Inc. (AMEX: HEB) today announced that William A. Carter, MD, Chairman & CEO, will present at the Fall 2006 Micro Cap Conference in New York City on Tuesday, September 19, at 10:30 AM EST. The Conference, sponsored by Friedland Capital, Inc., will be held at the Doubletree Suites Times Square, 1568 Broadway (47th Street & 7th Avenue).

Dr. Carter's presentation will recount the year-to-date achievements of Hemispherx Biopharma and the strategy going forward. The Company will continue to focus its efforts on three areas that have the greatest potential for revenue growth and corporate expansion.

1) Submitting the first new drug application (NDA) for the experimental drug Ampligen(R) for Chronic Fatigue Syndrome (CFS), one of the last severe chronic diseases without a recognized treatment. The Company is currently formulating a marketing strategy for potential distribution of Ampligen(R) for CFS.

2) The Company is also formulating a broad-spectrum biodefense strategy around the experimental agents Ampligen(R) and Alferon LDO (Low Dose Oral). The initial phase of this strategy is focused on avian and seasonal influenza.

3) Clinical efforts are focused to validate suggestions that Alferon N Injection(R), already approved for HPV-related genital warts, may have application in vulvar vestibulitis syndrome (VVS), an HPV-related disease. VVS is an ailment affecting approximately 14% of the female population in the U.S. and can also be severely debilitating.

Dr. Carter's presentation will be available on the Company's web site at http://hemispherx.net/ as of Tuesday, September 19.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx Biopharma's flagship products include Alferon(R) and the experimental drugs Ampligen(R), Alferon LDO and Oragens(TM). Alferon(R) is approved for a category of STD infection, and Ampligen(R) and Oragens(TM) represent experimental nucleic acids being developed for globally important diseases. Hemispherx's platform technology includes large and small agent components for potential treatment of various viral infections. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon(R) N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R), Alferon(R) LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.